Tuesday, July 24, 2012

Biotech Investor News Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

New York, New York - July 24, 2012 (Investorideas.com newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues follow-up commentary from Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) following recent news from the Company. Sunshine Biopharma reported it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Sunshine Biopharma's lead compound, Adva-27a, is a highly specific Topoisomerase II (Top2) Inhibitor and has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Q: Investorideas.com staff
Camille, your Company announced on July 20 th that it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. To the novice investor, can you explain what the significance of this is towards the development of Adva-27a as an actual drug?
A: Mr. Camille Sebaaly, CFO
At the end of the month, Sunshine Biopharma will take delivery from Beta Pharma Canada two items:
  • Adva-27a Compound
  • Scale-up Manufacturing Protocol
The Adva-27a Compound part of the delivery is the actual Adva-27a drug which Beta Pharma Canada had synthesized and put through rigorous structure validation and chemical characterization processes including HPLC, Mass Spec and NMR (H, F, COSY, HMQC) analyses. Sunshine Biopharma will perform specific biological analyses on the material for confirmation of biological activity. These are standard procedures in initial drug manufacturing processes.
The Scale-up Manufacturing Protocol, which is the second part of the delivery from Beta Pharma Canada, will be vetted by Sunshine Biopharma then transferred to the large-scale (over 1 kilogram range) manufacturer for large-scale process development and manufacturing under GMP conditions. The material produced under GMP conditions will be used by Sunshine Biopharma to conduct IND-Enabling Studies and Phase I Clinical Trials in humans.
Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Beta Pharma Canada
Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

No comments: